Clinical Trials Logo

Non-Small Cell Lunch Cancer clinical trials

View clinical trials related to Non-Small Cell Lunch Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT01820325 Terminated - Clinical trials for Non-Small Cell Lunch Cancer

Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer

BASALT-2
Start date: September 9, 2013
Phase: Phase 1
Study type: Interventional

The Phase Ib part of the study aimed to determine the maximum tolerated dose/recommended Phase II dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin and paclitaxel in patients with previously untreated metastatic squamous NSCLC. The purpose of the Phase II portion of the study was to assess the treatment effect of adding buparlisib versus buparlisib-matching placebo to every-three-week carboplatin and paclitaxel on progression free survival (PFS) in patients with previously untreated metastatic squamous NSCLC.